Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
UAB Pediatric Endocrinology (Part C and Part D), Birmingham, Alabama Ann and Robert H. Lurie Children's Hospital of Chicago (Part C and Part D), Chicago, Illinois Boston Children's Hospital (Part C only), Boston, Massachusetts Brigham and Women's Hospital (Part C and Part D), Boston, Massachusetts Vanderbilt University Medical Center (Part C only), Nashville, Tennessee